A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.

CHICAGO — Intraperitoneal (IP) chemotherapy is now an alternative to intravenous (IV) administration that "must be discussed" for women with cytoreduced ovarian cancer, several experts said here at ...

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial This was a multicenter randomized phase ...

Interest in the intraperitoneal delivery of chemotherapy to patients with ovarian cancer with minimal residual disease following initial cytoreductive surgery has been rekindled with the recent ...

A new guideline from ASCO updates evidence-based recommendations on the use of neoadjuvant chemotherapy and interval cytoreduction versus primary cytoreductive surgery (PCS) and chemotherapy in ...